• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Paxil CR: Paxil by any other name...

Paxil CR: Paxil by any other name...

January 1, 2003
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
The latest member of the “controlled-release club” is GlaxoSmithKline, with its Paxil CR. While cynics may believe that CR launches are simply efforts to prolong patent-lives and therefore profits, the reality is that CR formulations are generally better tolerated and easier to dose. This has certainly been the case for the antidepressants Wellbutrin SR and Effexor XR, as well as the multiple extended release stimulant and mood stabilizer preparations.

Now we have Paxil CR, with its “geomatrix” coating, allowing the tablet to pass through the stomach unaltered, so that most absorption occurs in the small intestine, where there are presumably fewer 5HT-3 receptors (the receptors that may be responsible for SSRI-induced nausea.)

Recently, the two pivotal clinical trials (those leading to FDA approval) for Paxil CR in the treatment of depression were reported in a single article in the Journal of Clinical Psychiatry (1). A total of 622 patients were assessed, and were randomly assigned to three groups: Paxil IR, Paxil CR, and placebo. These were 12 week trials (longer than the typical 6 to 8 week antidepressant trial), and at 12 weeks, average doses were: Paxil IR 38.2 mg, and Paxil CR 48.2 mg. The higher dose of CR probably reflects that fact that the geomatrix coating allows only 80% of the total amount of active drug to be absorbed, requiring higher dosages to achieve response. Using the LOCF (last observation carried forward) analysis, only Paxil CR (and not Paxil IR) bested placebo, both in terms of response rate (60% CR vs. 48% Placebo) and remission rates (45% CR, 34% Placebo).

So Paxil CR does work for depression, with response rates in line with typical SSRI depression trials. (The anemic performance of Paxil IR is somewhat concerning, and is not addressed by the authors). Other than this, the only really noteworthy finding was that fewer patients reported nausea during the first week on CR (14%) than IR (23%). However, by week two, there were no significant differences in nausea rates between the formulations. Otherwise, the CR preparation was plagued with all the usual side effects that have earned Paxil the reputation as the “high side effect” SSRI. 27% of Paxil CR patients reported abnormal ejaculation (placebo, 1%), 23% reported somnolence (placebo, 8%), and 19% reported dizziness (placebo, 5%).

One surprising finding was the lack of weight gain on either of the Paxils after 12 weeks. Those who have been following this controversial weight gain issue will remember a Journal of Clinical Psychiatry study in 2000 that showed Paxil causing significantly more weight gain than Zoloft or Prozac over 6 months (2). Perhaps the three months of follow-up for the current study was not long enough to detect weight gain, or perhaps Paxil-induced weight gain has been overblown. (Though I’d guess nine out of ten clinicians are anecdotally convinced that Paxil causes more weight gain than the other SSRIs).

So, what to say of Paxil CR? It’s probably just Paxil, but with a little less nausea for the first 7 days. Will this be enough of an advantage to choose brand name Paxil CR over Paxil IR when it becomes generic and cheaper? Highly doubtful.

TCR VERDICT: Patent ploy?

1. Golden RN, Nemeroff CB, McSorley P. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002;63:577-584.
2. Fava M, Judge R, Hoog SL, et. al. Fluoxetine versus Sertraline and Paroxetine in major depressive disorder: Change in weight with long-term treatment. J Clin Psychiatry 2000;61:863-867.
General Psychiatry
    Carlat 150x150
    Daniel Carlat, MD

    Prescribing Psychotropics: From Drug Interactions to Pharmacogenetics (2022)

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2006
    SUBSCRIBE NOW
    Table Of Contents
    Paxil CR
    Dr. John O’Reardon on Treatment-Resistant Depression
    Paxil CR: Paxil by any other name...
    Lexapro: The Son of Celexa
    Effexor XR: Is it really as good as they say it is?
    St. John’s Wort: Wilting in America
    The First Antidepressant
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto6759394.jpg
      General Psychiatry

      Throwback Thursday: Brief Therapy for ADHD

      You started a stimulant medication for a young woman with ADHD. When she returns her symptoms are 70% better, but what can we do about the rest? Today a conversation with...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.